617 related articles for article (PubMed ID: 28063788)
21. Clinical Targeted Next-Generation Sequencing Shows Increased Mutational Load in Endometrioid-type Endometrial Adenocarcinoma With Deficient DNA Mismatch Repair.
Lee PJ; McNulty S; Duncavage EJ; Heusel JW; Hagemann IS
Int J Gynecol Pathol; 2018 Nov; 37(6):581-589. PubMed ID: 29084048
[TBL] [Abstract][Full Text] [Related]
22. Outcome of chemotherapy with or without targeted agents in metastatic colorectal cancer patients with deficient DNA mismatch repair: A single center, cohort study.
Yu Y; Ying J; Zhang W; Li W; Sun Y; Yang L; Cui C; Zeng Y; Zhou A
Asia Pac J Clin Oncol; 2019 Jun; 15(3):128-135. PubMed ID: 30693649
[TBL] [Abstract][Full Text] [Related]
23. Complete pathological response after chemotherapy or immune checkpoint inhibitors in deficient MMR metastatic colorectal cancer: Results of a retrospective multicenter study.
Marolleau P; Tougeron D; Allignet B; Cohen R; Sefrioui D; Gallet B; Dumont F; Guimbaud R; Alouani E; Passot G; Desolneux G; Ghiringhelli F; Marchal F; Mourthadhoi F; Coriat R; Desgrippes R; Locher C; Goujon G; Des Guetz G; Aparicio T; Paubelle E; Dupré A; de la Fouchardière C
Int J Cancer; 2023 Oct; 153(7):1376-1385. PubMed ID: 37403609
[TBL] [Abstract][Full Text] [Related]
24. Mismatch Repair-Deficient Rectal Cancer and Resistance to Neoadjuvant Chemotherapy.
Cercek A; Dos Santos Fernandes G; Roxburgh CS; Ganesh K; Ng S; Sanchez-Vega F; Yaeger R; Segal NH; Reidy-Lagunes DL; Varghese AM; Markowitz A; Wu C; Szeglin B; Sauvé CG; Salo-Mullen E; Tran C; Patel Z; Krishnan A; Tkachuk K; Nash GM; Guillem J; Paty PB; Shia J; Schultz N; Garcia-Aguilar J; Diaz LA; Goodman K; Saltz LB; Weiser MR; Smith JJ; Stadler ZK
Clin Cancer Res; 2020 Jul; 26(13):3271-3279. PubMed ID: 32144135
[TBL] [Abstract][Full Text] [Related]
25. Clinicopathological features of mismatch repair protein expression patterns in colorectal cancer.
Lee CT; Chow NH; Chen YL; Ho CL; Yeh YM; Lin SC; Lin PC; Lin BW; Chu CA; Tsai HW; Lee JC
Pathol Res Pract; 2021 Jan; 217():153288. PubMed ID: 33276219
[TBL] [Abstract][Full Text] [Related]
26. The risk of developing a mismatch repair deficient colorectal cancer after undergoing cholecystectomy.
Halldorsson MO; Hauptmann M; Snaebjornsson P; Haraldsdóttir KH; Aspelund T; Gudmundsson EF; Gudnason V; Jonasson JG; Haraldsdottir S
Scand J Gastroenterol; 2018 Aug; 53(8):972-975. PubMed ID: 30010450
[TBL] [Abstract][Full Text] [Related]
27. Survival of Patients with Deficient Mismatch Repair Versus Proficient Mismatch Repair Metastatic Colorectal Cancer Receiving Curative-Intent Local Treatment of Metastases in a Nationwide Cohort.
Zwart K; van der Baan FH; Punt CJA; Wensink GE; Bolhuis K; Laclé MM; van Grevenstein WMU; Hagendoorn J; de Hingh IH; Koopman M; Vink G; Roodhart J
Ann Surg Oncol; 2023 Oct; 30(11):6762-6770. PubMed ID: 37528303
[TBL] [Abstract][Full Text] [Related]
28. Mismatch Repair Deficient (dMMR) Colorectal Carcinoma in a Pakistani Cohort: Association With Clinical and Pathological Parameters.
Hashmi AA; Bukhari U; Rizwan R; Faisal F; Kumar R; Malik UA; Zia S; Khan AR; Sham S; Irfan M
Cureus; 2023 Aug; 15(8):e42781. PubMed ID: 37664303
[TBL] [Abstract][Full Text] [Related]
29. Prognostic and predictive roles of DNA mismatch repair status in colon cancer patients treated with oxaliplatin-based chemotherapy: a retrospective study.
Qin Q; Zhou AP; Yang L; Xu C; Sun YK; Zhang W; Wang JW; Zhong DS
J Physiol Pharmacol; 2020 Aug; 71(4):. PubMed ID: 33316771
[TBL] [Abstract][Full Text] [Related]
30. Tumor Budding
Karlberg M; Stenstedt K; Hallström M; Ragnhammar P; Lenander C; Edler D
Anticancer Res; 2018 Aug; 38(8):4713-4721. PubMed ID: 30061240
[TBL] [Abstract][Full Text] [Related]
31. A relationship to survival is seen by combining the factors of mismatch repair status, tumor location and age of onset in colorectal cancer patients.
Li P; Xiao Z; Braciak TA; Ou Q; Chen G; Oduncu FS
PLoS One; 2017; 12(3):e0172799. PubMed ID: 28253296
[TBL] [Abstract][Full Text] [Related]
32. Prognosis of microsatellite instability and/or mismatch repair deficiency stage III colon cancer patients after disease recurrence following adjuvant treatment: results of an ACCENT pooled analysis of seven studies.
Taieb J; Shi Q; Pederson L; Alberts S; Wolmark N; Van Cutsem E; de Gramont A; Kerr R; Grothey A; Lonardi S; Yoshino T; Yothers G; Sinicrope FA; Zaanan A; André T
Ann Oncol; 2019 Sep; 30(9):1466-1471. PubMed ID: 31268130
[TBL] [Abstract][Full Text] [Related]
33. Risk of secondary malignancy (including breast) in patients with mismatch-repair protein deficiency.
Clay MR; Allison KH; Folkins AK; Longacre TA
Am J Surg Pathol; 2014 Nov; 38(11):1494-500. PubMed ID: 24921635
[TBL] [Abstract][Full Text] [Related]
34. Survival of patients with deficient mismatch repair metastatic colorectal cancer in the pre-immunotherapy era.
Wensink GE; Elferink MAG; May AM; Mol L; Hamers PAH; Bakker SD; Creemers GJ; de Groot JWB; de Klerk GJ; Haberkorn BCM; Haringhuizen AW; Hoekstra R; Hunting JCB; Kerver ED; Mathijssen-van Stein D; Polée MB; Pruijt JFM; Quarles van Ufford-Mannesse P; Radema S; Rietbroek RC; Simkens LHJ; Tanis BC; Ten Bokkel Huinink D; Tjin-A-Ton MLR; Tromp-van Driel CS; Troost MM; van de Wouw AJ; van den Berkmortel FWPJ; van der Pas AJM; van der Velden AMT; van Dijk MA; van Dodewaard-de Jong JM; van Druten EB; van Voorthuizen T; Jan Veldhuis G; Verheul HMW; Vestjens HJHMJ; Vincent J; Kranenburg OW; Punt CJA; Vink GR; Roodhart JML; Koopman M
Br J Cancer; 2021 Jan; 124(2):399-406. PubMed ID: 33046804
[TBL] [Abstract][Full Text] [Related]
35. Is Adjuvant Chemotherapy Necessary for Patients with Deficient Mismatch Repair Gastric Cancer?-Autophagy Inhibition Matches the Mismatched.
Tsai CY; Lin TA; Huang SC; Hsu JT; Yeh CN; Chen TC; Chiu CT; Chen JS; Yeh TS
Oncologist; 2020 Jul; 25(7):e1021-e1030. PubMed ID: 32058649
[TBL] [Abstract][Full Text] [Related]
36. Defective Mismatch Repair Status was not Associated with DFS and OS in Stage II Colon Cancer Treated with Adjuvant Chemotherapy.
Kim JE; Hong YS; Kim HJ; Kim KP; Lee JL; Park SJ; Lim SB; Park IJ; Kim CW; Yoon YS; Yu CS; Kim JC; Hoon KJ; Kim TW
Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S630-7. PubMed ID: 26271397
[TBL] [Abstract][Full Text] [Related]
37. Association Between Survival and Metastatic Site in Mismatch Repair-Deficient Metastatic Colorectal Cancer Treated With First-line Pembrolizumab.
Saberzadeh-Ardestani B; Jones JC; Hubbard JM; McWilliams RR; Halfdanarson TR; Shi Q; Sonbol MB; Ticku J; Jin Z; Sinicrope FA
JAMA Netw Open; 2023 Feb; 6(2):e230400. PubMed ID: 36811859
[TBL] [Abstract][Full Text] [Related]
38. Mismatch Repair Status Correlates with Survival in Young Adults with Metastatic Colorectal Cancer.
van der Heide DM; Turaga KK; Chan CHF; Sherman SK
J Surg Res; 2021 Oct; 266():104-112. PubMed ID: 33989889
[TBL] [Abstract][Full Text] [Related]
39. Sporadic endometrial adenocarcinoma with MMR deficiency due to biallelic MSH2 somatic mutations.
Buecher B; De Pauw A; Bazire L; Houdayer C; Fievet A; Moncoutier V; Farkhondeh F; Melaabi S; Lyonnet DS; Golmard L
Fam Cancer; 2018 Apr; 17(2):281-285. PubMed ID: 28819700
[TBL] [Abstract][Full Text] [Related]
40. A Phase II Study of Avelumab Monotherapy in Patients with Mismatch Repair-Deficient/Microsatellite Instability-High or POLE-Mutated Metastatic or Unresectable Colorectal Cancer.
Kim JH; Kim SY; Baek JY; Cha YJ; Ahn JB; Kim HS; Lee KW; Kim JW; Kim TY; Chang WJ; Park JO; Kim J; Kim JE; Hong YS; Kim YH; Kim TW
Cancer Res Treat; 2020 Oct; 52(4):1135-1144. PubMed ID: 32340084
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
